NR1H4 and metabolic dysfunction-associated steatohepatitis: Further investigation into the short-term and long-term effects of OCA on liver function and injury are warranted and are actively being explored in the Randomized Global Phase III Study to Evaluate the Impact on NASH with Fibrosis of Obeticholic Acid Treatment (REGENERATE) clinical trial assessing FXR activation in the treatment of NASH (71).